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Acquired somatic mutations in hematopoietic stem and progenitor cells (clonal hematopoi-
esis or CH) are associated with advanced age, increased risk of cardiovascular and malignant
diseases, and decreased overall survival. These adverse sequelae may be mediated by altered
inflammatory profiles observed in patients with CH. A pro-inflammatory immunologic profile
is also associated with worse outcomes of certain infections, including SARS-CoV-2 and its
associated disease Covid-19. Whether CH predisposes to severe Covid-19 or other infections
is unknown. Among 525 individuals with Covid-19 from Memorial Sloan Kettering (MSK) and
the Korean Clonal Hematopoiesis (KoCH) consortia, we show that CH is associated with
severe Covid-19 outcomes (OR= 1.85, 95%=1.15–2.99, p= 0.01), in particular CH char-
acterized by non-cancer driver mutations (OR= 2.01, 95% CI= 1.15–3.50, p= 0.01). We
further explore the relationship between CH and risk of other infections in 14,211 solid tumor
patients at MSK. CH is significantly associated with risk of Clostridium Difficile (HR= 2.01,
95% CI: 1.22–3.30, p= 6×10−3) and Streptococcus/Enterococcus infections (HR= 1.56, 95%
CI= 1.15–2.13, p= 5×10−3). These findings suggest a relationship between CH and risk of
severe infections that warrants further investigation.
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Acquired mutations that lead to clonal expansion are com-mon in the normal aging hematopoietic system (clonalhematopoiesis, or CH), yet are known to alter stem/pro-
genitor and lymphoid function and response to environmental
stressors, including systemic infections1–4. The mutational events
that drive CH overlap with known drivers of hematologic malig-
nancies. However, the majority of mutations in CH appear to occur
outside of canonical cancer driver genes5,6. The impact of individual
mutational events on hematopoietic stem and progenitor cells differs
by the nature of the genomic aberration. For example, chromosomal
aneuploidies result in a predisposition for lymphoid fate specifica-
tion and transformation7,8, whereas point mutations in DNMT3A
result in increased myeloid differentiation9. Heterogeneity also exists
across CH phenotypes by driver gene in regards to its impact on
inflammatory signaling2. For example, mutations in TET2 result in
the heightened secretion of several cytokines including IL-1β/IL-
6 signaling that may partially explain the increased risk of cardio-
vascular disease1,3,10. Moreover, systemic infections and the resultant
inflammatory signals can lead to increased clonal fitness of TET2
mutant cells and clonal expansion4,11,12. Despite these important
insights, the relationship between different CH-associated mutations,
infectious disease risk, and severity has not been studied. The
severity of Covid-19 is also associated with advanced age, cardio-
vascular disease, and elevated circulating IL-6 levels; features that are
also associated with CH13–17. Given the common inflammatory
profile of CH and severe Covid-19 infection, we investigated the
relationship between CH and Covid-19 disease severity. We went on
to study the relationship between CH and other serious infections.
Here, we show that CH is associated with an increased risk of
severe Covid-19 outcomes in a cohort of solid tumor patients and
healthy individuals. Within solid tumor patients, CH is associated
with an increased risk of Clostridium Difficile and Streptococcus/
Enterococcus infections.
Results
Patient characteristics, CH, and Covid-19 assessment. Our
study included patients from two separate cohorts. The first
cohort was composed of patients with solid tumors treated at
Memorial Sloan Kettering Cancer Center (MSK) with blood
previously sequenced using MSK-IMPACT, a previously vali-
dated targeted gene panel capturing all commonly mutated CH-
associated genes (Supplementary Data 1)18. Of these patients,
1636 were tested for SARS-CoV-2 (the virus that causes Covid-
19) RNA between 1st March 2020 and 1st July 2020; 413 (25%)
individuals tested positive for SARS-CoV-2 (Methods and
Table 1). The second cohort included 112 previously healthy
individuals without cancer who were hospitalized for Covid-19
between January and April 2020 at four tertiary hospitals in South
Korea (KoCH cohort). The KoCH cohort was sequenced using a
custom targeted NGS panel from Agilent (89 genes), which was
designed to include commonly occurring CH genes (Supple-
mentary Data 2).
For both cohorts, the primary outcome was severe Covid-19
infection, defined as the presence of hypoxia requiring >1 L
supplemental oxygen with documented hypoxia (oxygen satura-
tion <94%). To determine the association between severe Covid-
19 and CH separately in each cohort, we used multivariable
logistic regression adjusting for covariates including age, gender,
smoking, and prior Covid-19-related comorbidities including
cardiovascular disease, hypertension, and chronic obstructive
pulmonary disease (COPD)/asthma. The MSK cohort was also
adjusted for cancer primary site and exposure to cytotoxic cancer
therapy before and after blood draw. We then performed a fixed-
effects meta-analysis to estimate the association in the overall
population. The full statistical rationale is further described in the
Methods section.
Association of CH with severe Covid-19 infections. Among
Covid-19-positive individuals, 23% (N= 94) and 61% (N= 68)
had severe disease in the MSK and KoCH cohorts, respectively
(Table 1, Supplementary Fig. 1). Overall, CH was observed in 35%
of Covid-19-positive cases at MSK and 21% in KoCH. Of note,
when restricting the MSK-IMPACT panel to the 89 genes
included in the KoCH panel, 20% of Covid-19-positive cases at
MSK had CH. In the MSK cohort, CH was observed in 51% and
30% of patients with severe versus non-severe Covid-19, respec-
tively (adjusted OR: 1.85, 95% CI 1.10–3.12, p= 0.02) (Fig. 1). A
sensitivity analysis of the MSK data limited to hospitalized
patients (N= 117) yielded similar, albeit non-significant, results
(OR= 1.6; 95% CI= 0.5–5.2). In the KoCH cohort, CH was
observed in 25% and 16% of patients with severe versus non-
severe Covid-19, respectively, (adjusted OR 1.85, 95% CI
0.53–6.43, p= 0.33) (Fig. 1). In a fixed-effects meta-analysis of
odds ratio estimates from the multivariable logistic regression
models employed in each separate cohort analysis, the presence of
CH was associated with an increased risk of severe Covid-19
(OR= 1.85, 95%= 1.15–2.99, p= 0.01) (Fig. 1). We did not see
evidence of heterogeneity in the strength of the association in the
MSK and KoCH cohorts. This is in line with evidence of simi-
larity in predictors of Covid-19 severity in cancer and non-cancer
populations13,19–21 but requires further examination in larger
cohorts. The odds ratio we observed between CH and severe
Covid-19 we observed is similar to that previously reported by
Hameister et al.22 (OR= 1.2; 95% CI= 0.5–3.0).
Using previously described methods18, CH mutations were
classified as known or hypothesized cancer putative drivers (PD-
CH) or non-putative drivers (non-PD-CH). In order to explore
the association between particular mutation types and Covid-19
severity, we performed a stratified analysis of Covid-19 severity by
PD-CH versus non-PD-CH status using multivariate logistic
regression including the covariates from the main model. A
significant association was observed between non-PD-CH and
severe Covid-19 (OR= 2.01, 95% CI= 1.15–3.50, p= 0.01), as
well as between silent (synonymous) CH and severe Covid-19
(OR= 2.58, 95% CI 1.01–6.61, p= 0.05) (Supplementary Fig. 2).
There was not a statistically significant association between PD-
CH and severe Covid-19 infection (OR= 1.15, 95%
CI= 0.61–2.02, p= 0.62) (Supplementary Fig. 2). Most non-PD
mutations in severe Covid-19 cases occurred in non-recurrently
mutated genes (65% at MSK and 77% in KoCH, Supplementary
Fig. 3). In additional exploratory analyses, we characterized the
association between CH variant allele frequency (VAF), mutation
number, and severe Covid-19. The strength of the association
between CH and severe Covid-19 was similar among patients
with one CH mutation (OR= 1.78, 95% CI= 1.02–3.09,
p= 0.04) and multiple CH mutations (OR= 1.97, 95%
CI= 1.03–3.78, p= 0.04) (Supplementary Fig. 4). Patients with
a maximum CH VAF of >5% showed a significant association
with severe Covid-19 (OR= 1.89, 95% CI= 1.04–3.43, p= 0.04,
Supplementary Fig. 5). In an exploratory analysis, we also
observed a significant association between the risk of invasive/
non-invasive ventilation and non-driver CH (OR= 2.18, 95% CI
1.08–4.40, p= 0.03: Supplementary Fig. 6). These data suggest
that the presence of CH and resultant alterations in hematopoie-
tic differentiation, and not specific mutant alleles, is predictive of
Covid-19 disease severity.
To study whether exposure to chemotherapy might modify the
relationship between non-PD-CH, PD-CH, and Covid-19
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severity, we performed a series of stratified analyses by prior
exposure to cytotoxic chemotherapy within the MSK cohort. We
observed a similar enrichment of non-PD-CH among individuals
with severe Covid-19 among those exposed to cytotoxic therapy
(2.12, 95% CI 0.71–6.22, p= 0.17) and unexposed (1.88, 95% CI
0.98–3.90, p= 0.09). The relationship between non-PD-CH and
Covid-19 severity did not appear to be greatly modified by
exposure to cytotoxic therapy. Similar to our findings overall for
CH-PD, among those not previously exposed to chemotherapy,
no association was observed between CH-PD and Covid-19
severity (OR= 0.82, 95% CI 0.34–1.83, p= 0.63). We did,
however, observe a non-significant trend towards a positive
association between CH-PD and Covid-19 severity among those
previously exposed to chemotherapy (OR= 2.4, 95% CI
0.86–6.74, p= 0.09). Of note, we also observed a trend towards
a higher proportion of individuals with CH-PD mutations in
PPM1D among those with severe Covid-19 (5%, N= 5)
compared with non-severe Covid-19 (1%, N= 2) (Supplementary
Fig. 7). This provides some evidence that CH-PD in cancer
patients with severe Covid-19 may reflect poor hematopoietic
reserve after chemotherapy and in turn worse immune response
to infection. However, this would require further investigation in
larger populations of cancer patients.
Association between CH and risk of diverse infections. Given
the evidence of an association between CH and Covid-19 severity,
we sought to explore the relationship between CH and other types of
infections. We analyzed billing codes from 14,211 solid tumor
Table 1 Characteristics of study participants.
MSK KoCH
Severe covid Non-severe covid Negative Untested Severe covid Non-severe covid
(N= 94) (N= 319) (N= 1223) (N= 7681) (N= 68) (N= 44)
Age(y)
0–50 12 (12.8%) 84 (26.3%) 308 (25.2%) 1712 (22.3%) 6 (8.8%) 16 (36.4%)
50–60 17 (18.1%) 93 (29.2%) 303 (24.8%) 1741 (22.7%) 10 (14.7%) 6 (13.6%)
60–70 32 (34.0%) 83 (26.0%) 356 (29.1%) 2358 (30.7%) 23 (33.8%) 8 (18.2%)
70–80 28 (29.8%) 46 (14.4%) 211 (17.3%) 1523 (19.8%) 15 (22.1%) 9 (20.5%)
80+ 5 (5.3%) 13 (4.1%) 45 (3.7%) 347 (4.5%) 14 (20.6%) 5 (11.4%)
Gender
Female 54 (57.4%) 169 (53.0%) 675 (55.2%) 4569 (59.5%) 28 (41.2%) 23 (52.3%)
Male 40 (42.6%) 150 (47.0%) 548 (44.8%) 3112 (40.5%) 40 (58.8%) 21 (47.7%)
Smoking
Never 38 (40.4%) 157 (49.2%) 565 (46.2%) 3687 (48.0%) 34 (50.0%) 30 (68.2%)
Current/former 55 (58.5%) 154 (48.3%) 639 (52.2%) 3910 (50.9%) 10 (14.7%) 13 (29.5%)
Missing 1 (1.1%) 8 (2.5%) 19 (1.6%) 84 (1.1%) 24 (35.3%) 1 (2.3%)
Hypertension
No 38 (40.4%) 183 (57.4%) 673 (55.0%) 4422 (57.6%) 34 (50.0%) 26 (59.1%)
Yes 56 (59.6%) 136 (42.6%) 550 (45.0%) 3259 (42.4%) 34 (50.0%) 18 (40.9%)
Coronary artery disease
No 80 (85.1%) 285 (89.3%) 1104 (90.3%) 7058 (91.9%) 63 (92.6%) 40 (90.9%)
Yes 14 (14.9%) 34 (10.7%) 119 (9.7%) 623 (8.1%) 5 (7.4%) 4 (9.1%)
COPD/asthma
No 78 (83.0%) 271 (85.0%) 1030 (84.2%) 6531 (85.0%) 64 (94.1%) 41 (93.2%)
Yes 16 (17.0%) 48 (15.0%) 193 (15.8%) 1150 (15.0%) 4 (5.9%) 3 (6.8%)
Diabetes
No 72 (76.6%) 256 (80.3%) 1039 (85.0%) 6681 (87.0%) 48 (70.6%) 36 (81.8%)
Yes 22 (23.4%) 63 (19.7%) 184 (15.0%) 1000 (13.0%) 20 (29.4%) 8 (18.2%)
Race
White 54 (57.4%) 199 (62.4%) 912 (74.6%) 5728 (74.6%) 0 (0.0%) 0 (0.0%)
Missing 5 (5.3%) 24 (7.5%) 52 (4.3%) 331 (4.3%) 0 (0.0%) 0 (0.0%)
Non-White 35 (37.2%) 96 (30.1%) 259 (21.2%) 1622 (21.1%) 68 (100%) 44 (100%)
Month of Covid Dx
January 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (2.9%) 6 (13.6%)
February 0 (0.0%) 0 (0.0%) 0 (0.0%) 14 (20.6%) 9 (20.5%)
April 47 (50.0%) 141 (44.2%) 246 (20.1%) 1 (1.5%) 5 (11.4%)
March 44 (46.8%) 93 (29.2%) 89 (7.3%) 26 (38.2%) 13 (29.5%)
May 3 (3.2%) 75 (23.5%) 681 (55.7%) 5 (7.4%) 8 (18.2%)
June 0 (0%) 10 (3.1%) 206 (16.8%) 20 (29.4%) 3 (6.8%)
Missing 0 (0%) 0 (0%) 1 (0.1%)
BMI (mean) 27.5 28.2 26.5 27.8 23.5 23.7
Cytotoxic therapy prior to blood draw
No 59 (62.8%) 199 (62.4%) 742 (60.7%) 5549 (72.2%)
Yes 35 (37.2%) 120 (37.6%) 481 (39.3%) 2132 (27.8%)
Cytotoxic therapy after blood draw
No 30 (31.9%) 130 (40.8%) 349 (28.5%) 4208 (54.8%)
Yes 64 (68.1%) 189 (59.2%) 874 (71.5%) 3473 (45.2%)
Primary tumor site
Other 66 (70.2%) 266 (83.4%) 927 (75.8%) 6097 (79.4%)
Thoracic 28 (29.8%) 53 (16.6%) 296 (24.2%) 1584 (20.6%)
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patients treated at MSK who underwent blood sequencing by MSK-
IMPACT. Using a previously established phenome-wide association
study methodology23, we mapped patient ICD-9 and ICD-10 billing
codes to categories of infectious disease. Multivariable Cox pro-
portional hazards regression was used to estimate the hazard ratio
(HR) for risk of infection among CH-positive compared with CH-
negative individuals. All models were adjusted for age, race, smok-
ing, gender, cumulative to cytotoxic therapy prior to blood draw,
cumulative exposure to cytotoxic therapy after blood draw, and
primary tumor site. Given the number of model covariates, we
limited the analysis to 32 infection subclasses that affected at least 80
individuals (see Methods). Multiple infection types were associated
with CH, although many associations were not statistically sig-
nificant after adjustment for multiple testing (Fig. 2A, Supplemen-
tary Data 3). CH was significantly (false-discovery rate (FDR)-
corrected p value < 0.10) associated with the onset of two infection
subclasses: C. difficile infection (HR= 2.01, 95% CI: 1.22–3.30,
p= 6 × 10−3) and Streptococcus/Enterococcus infection (HR= 1.56,
95% CI= 1.15–2.13, p= 5 × 10−3). When stratified by CH-
mutation characteristics, patients with two or more CH mutations
had a stronger association with C. difficile infection (OR= 3.37, 95%
CI= 1.79–6.33, p= 2 × 10−4) compared with patients with one CH
mutation (OR= 1.42, 95% CI= 0.75–2.67, p= 0.28). The associa-
tion between CH and C. difficile infection was significant for
mutations with a VAF of >5% (OR= 2.54, 95% CI= 1.39-4.63,
p= 0.002) but not mutations with a VAF of 2–5% (OR= 1.59, 95%
CI= 0.83–3.05, p= 0.17). Similar to Covid-19 severity, the asso-
ciation between CH and C. difficile infection was significant for non-
PD-CH (OR= 2.11, 95% CI= 1.25–3.59, p= 0.01) and silent
mutations (OR= 2.64, 95% CI= 1.20–5.80, p= 0.02) but not CH-
PD (OR= 1.42, 95% CI= 0.74–2.82, p= 0.39) (Fig. 2B). Given the
strong relationship between prior antibiotic use and C. difficile
infection risk, we performed a sensitivity analysis including the
number of courses of antibiotics received after MSK-IMPACT blood
draw. There was no clear association between CH and antibiotic use
and no effect of inclusion of this as a covariate in the model
(Supplementary Fig. 8).
Discussion
In summary, we show that CH is associated with increased
Covid-19 severity in a heterogeneous, international cohort of
cancer and non-cancer patients. In a large cancer patient cohort,
CH is also associated with other severe infections, namely
Streptococcus/Enterococccus and C. difficile infections. Future
studies in large patient populations are needed to further char-
acterize the association between CH and infection severity and
whether this might differ in cancer compared with non-cancer
populations and by other patient characteristics including race
and age among others. Our exploratory analysis suggests that the
relationship between CH and Covid-19 and CH and C. difficile
infection may be partly driven by non-driver CH. Clonal
expansions characterized by non-driver mutational events could
be facilitated by multiple mechanisms. Many classes of genetic
alterations, such as copy number events (CNVs), structural var-
iants, non-coding, and epigenetic changes, are not detectable
using the targeted panels included in this study. As such, the
observed events that are highly enriched in CH could be “pas-
senger” mutations that co-occur with a positively selected,
undetected “driver” mutation such as recurrent CNVs6,7. Alter-
natively, driver mutations may have been incompletely classified
as “non-driver” events using our methodology. However, cancer
driver genes tend to recur in multiple patients, and the majority
of witnessed non-driver mutated genes in our cohort were non-
recurrent suggesting that clonal expansion, and not the specific
event driving clonal expansion, may be associated with Covid-19
disease severity. Owing to the small sample sizes, the association
between CH, infection risk, and Covid-19 severity, including
differences by gene and driver mutation status, will need to be
further studied in larger cohorts.
The hematopoietic system is a key regulator of inflammation
and immunity. A substantial body of evidence now links somatic
alterations in hematopoietic stem and progenitor cells to a variety
of health outcomes, with inflammation emerging as a key
mediator2–5,10–13. Our data, along with results in the manuscript
by Zekavat et al.24, demonstrate a similar association between
CH, risk of severe Covid-19, and certain infection types. This
association may be due to residual confounding by variables that
are unknown and unaccounted for in our models. Even in this
situation, CH as a biomarker of poor outcome could be a useful
clinical predictor. Alternatively, this could be owing to CH-
induced changes in the hematopoietic stem, progenitor, and
lymphoid cell function impacting immune regulation and infec-
tion response. Shared and/or distinct processes may underlie the
Fixed effects model
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Fig. 1 Association between CH and Covid-19 severity. Shown are the results from logistic regression adjusted for age, gender, race, smoking, diabetes,
cardiovascular disease, COPD/asthma, BMI, and month of Covid-19 diagnosis in 525 individuals. The MSK cohort was also adjusted for cancer primary site,
exposure to cytotoxic cancer therapy before and after blood draw. Summary statistics for a fixed-effects meta-analysis are shown. Any CH includes both
driver (CH-PD) and non-driver mutations (CH-non-PD).
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associations we observed between CH, Covid-19 severity, and
infection risk. Future investigation including functional studies
will be important to clarify these mechanisms and to develop
potential interventional strategies to attenuate inflammation,
clonal expansion, and infectious sequelae in patients with and
without cancer.
Methods
Sample ascertainment and clinical data extraction
MSK cohort. Subjects had a tumor and blood sample (as a matched control)
sequenced using MSK-IMPACT on an institutional prospective tumor-sequencing
protocol (ClinicalTrials.gov number, NCT01775072) before July 1st 2019. This
study was approved by the MSKCC Institutional Review Board (IRB). A subset of
patients who underwent tumor genomic profiling as the standard of care did not
directly consent in which case an IRB waiver was obtained to allow for inclusion
into this study. The study population for Covid-19 analyses included a subset of
9,307 patients with non-hematologic cancers who were alive on 1st March 2020.
Subjects who had a hematologic malignancy diagnosed after MSK-IMPACT testing
or who had an active hematologic malignancy at the time of blood draw were
excluded. Demographics, smoking history, exposure to oncologic therapy, and
primary tumor site were extracted from the electronic health record (EHR). The
accuracy of populated information was manually checked in the EHR by three
independent physicians (K.B., M.F, A.S.). The presence of co-existing medical
comorbidities known to correlate with Covid-19 severity including diabetes,
COPD, asthma, hypertension, and cardiovascular disease, were ascertained from
ICD-9 and ICD-10-billing codes. SARS-CoV-2 status was determined using RT-
PCR from laboratory records available through the MSK EHR. SARS-CoV-2
testing was performed both in the inpatient and outpatient settings. We defined
severe Covid-19 as the presence of hypoxia requiring supplemental oxygen (sup-
plemental oxygen device >1 L with oxygen saturation <94%) resulting from Covid-
19 infection. Hypoxia was selected as our measure of disease severity due to the
frequency of its occurrence and since it was based on an objective measure (i.e.,
oxygen saturation). There were seven subjects with Covid-19 for whom there was
minimal documentation of clinical course following Covid-19 infection and these
individuals were excluded. There were three individuals with metastatic cancer and
progression of disease at the time of Covid-19 where it was unclear whether
documented hypoxia could be attributed to Covid-19 or disease progression. These
subjects were also excluded. For future studies, we also provide individual-level
data in regards to Covid-19 related mortality (see data availability for data access).
KoCH cohort. Laboratory-confirmed patients with Covid-19 who were hospitalized
between January and April 2020 in four tertiary hospitals in the Republic of Korea
were approached for consent to this study. Blood was drawn following confirma-
tion of Covid-19 positivity. All four hospitals have been running national-
designated isolation units, which are located in Seoul, Gyeonggi, or Daegu. These
provinces had the highest numbers of Covid-19 cases during the period14. The
indications for hospitalization in the KoCH cohort during this time period were
complex and, in some situations, individuals who were asymptomatic or minimally
symptomatic were hospitalized. Clinical and laboratory characteristics were ret-
rospectively reviewed using the electronic medical record systems of each institu-
tion. Hypoxia requiring supplemental oxygen was defined as supplemental oxygen
device >1 L with oxygen saturation <94%, resulting from Covid-19 infection. The
Seoul National University Hospital IRB, Seoul National University Bundang
Hospital IRB, National Medical Center IRB, and Kyungpook National University
Hospital IRB approved the study (IRB numbers 2003-141-1110, B-2006/616-409,
NMC-2008-050, KNUH-2020-04-069-001, respectively). Written informed consent
for all participants was obtained per IRB recommendations. Subjects who had an
active malignancy at the time of blood draw were excluded.
Sequencing and variant calling
MSK cohort. MSK-IMPACT is an FDA-authorized hybridization capture-based
next-generation sequencing assay encompassing all protein-coding exons from the
canonical transcript of 341, 410, or 468 cancer-associated genes (Supplementary
Data 1). MSK-IMPACT is validated and approved for clinical use by New York
State Department of Health Clinical Laboratory Evaluation Program. The
sequencing test utilizes genomic DNA extracted from formalin-fixed paraffin-
embedded (FFPE) tumor tissue as well as matched patient blood samples. DNA is
sheared and DNA fragments are captured using custom probes. MSK-IMPACT
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Fig. 2 Association between CH and risk of infection in 14,211 solid tumor patients. A Volcano plot of the log(Hazard ratio) of infection with CH using
multivariable cox proportional hazards regression. Any CH includes both driver (CH-PD) and non-driver mutations (CH-non-PD). B Association between
CH subtype defined by CH putative driver status and risk of Clostridium Difficle (N= 189) and Streptococcus/Enterococcus (N= 501) infection using cox
proportional hazards regression. All models were adjusted for age, gender, race, smoking, cancer primary site, cumulative exposure to cytotoxic cancer
therapy before and after blood draw. Shown is the hazard ratio for infection, associated 95% confidence interval, and p value (not adjusted or multiple
comparisons).
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versions of the panel did not contain PPM1D or SRSF2 (5% of individuals were
sequenced on this earlier version).
Pooled libraries were sequenced on an Illumina HiSeq 2500 with 2 × 100 bp
paired-end reads. Sequencing reads were aligned to the human genome (hg19)
using BWA (0.7.5a). Reads were realigned around indels using ABRA (0.92),
followed by base-quality score recalibration with Genome Analysis Toolkit
(GATK) (3.3-0). Median coverage in the blood samples was 497×, and median
coverage in the tumors was 790×. Variant calling for each blood sample was
performed unmatched, using a pooled control sample of DNA from 10 unrelated
individuals as a comparator. Single-nucleotide variants (SNVs) were called using
Mutect (1.1.4) and VarDict (1.4.6). Insertions and deletions were called using
Somatic Indel Detector (2.3) and VarDict. Variants that were called by two callers
were retained. Dinucleotide substitution variants were detected by VarDict and
retained if any base overlapped an SNV called by Mutect. All called mutations were
genotyped in the patient-matched tumor sample. Mutations were annotated with
VEP (version 86) and OncoKb. We applied a series of post-processing filters to
further remove false-positive variants caused by sequencing artifacts and putative
germline polymorphisms as previously described18 and as detailed in the
Supplemental Methods section.
KoCH cohort. Blood-derived DNA was sequenced using a custom panel of 89 genes
frequently mutated in CH. All NGS libraries were prepared using the Agilent
SureSelect XT HS and XT Low input enzymatic fragmentation kit. Pooled Libraries
were sequenced on an Illumina NovaSeq6000 with 2 × 150 bp paired-end reads.
Sequencing reads were trimmed with SeqPrep (v0.3) and Sickle (v1.33) and aligned
to the human genome (hg19) using BWA-MEM (v0.7.10). PICARD(v1.94) was
used for duplicate marking followed by indel realignment and base-quality score
recalibration with GATK light(v2.3.9). The mean depth of coverage of samples was
higher than 800×. Variant calling was performed using SNver(v0.4.1),
LoFreq(v0.6.1), GATK UnifiedGenotyper(v2.3.9) for SNVs. For Insertions and
deletions, in-house caller was used25.
Variant annotation. Variants from the MSK and KoCH cohort were uniformly
annotated according to evidence for functional relevance in cancer (putative driver
or CH-PD). We annotated variants as oncogenic if they fulfilled any of the fol-
lowing criteria: (1) truncating variants in NF1, DNMT3A, TET2, IKZF1, RAD21,
WT1, KMT2D, SH2B3, TP53, CEBPA, ASXL1, RUNX1, BCOR, KDM6A, STAG2,
PHF6, KMT2C, PPM1D, ATM, ARID1A, ARID2, ASXL2, CHEK2, CREBBP, ETV6,
EZH2, FBXW7, MGA, MPL, RB1, SETD2, SUZ12, ZRSR2 or in CALR exon 9; (2)
any truncating mutations (nonsense, essential splice site or frameshift indel) in
known tumor suppressor genes as per the Cancer Gene Census, OncoKB, or the
scientific literature; (3) translation start site mutations in SH2B3; (4) TERT pro-
moter mutations; (5) FLT3-ITDs; (6) in-frame indels in CALR, CEBPA, CHEK2,
ETV6, EZH2; (7) any variant occurring in the COSMIC “haematopoietic and
lymphoid” category greater than or equal to 10 times; (8) any variant reported as
somatic at least 20 times in COSMIC; (9) any variant noted as potentially onco-
genic in an in-house data set of 7000 individuals with myeloid neoplasm greater
than or equal to five times; (10) any loci (defined by the amino-acid location)
reported as having at least five missense mutations and at least one exact muta-
tional match in TopMed2.
Post-processing filters for CH calling
MSK cohort. We applied a series of post-processing filters to further remove false-
positive variants caused by sequencing artifacts and putative germline poly-
morphisms. We removed variants that were found (with a VAF of >2% at least
once) in a panel of sequencing data from 300 blood samples obtained from persons
under 20 year of age and without evidence of CH. We further filtered single-
nucleotide deletions within a homopolymer stretch (≥3 base repetition) of the same
deleted base pair, single-nucleotide substitutions completing a stretch of a ≥5-base-
pair-long homopolymer (for example, GGCGG→GGGGG), in-frame deletions, or
insertions in a highly repetitive region (DUST algorithm score of ≥5) and variants
with unequal proportions of forward/reverse direction supporting reads based on a
Fisher test. We performed a manual review in Integrative Genomics Viewer of
recurrent mutations not previously reported in public databases. We required a
VAF of at least 2% and at least ten supporting reads. All genotypes were calculated
using sequencing reads and bases with a quality value of at least 20. Because
somatic mutations in the blood would be expected to be detected in the blood but
not in other tissue compartments, we compared the VAF of mutations in the blood
compared with the matched tumor. Variant calls that were present in the blood
with a VAF of at least twice that in the tumor, or 1.5 times the VAF if the tumor
biopsy site was a lymph node, were considered somatic. This ratio was chosen
based on maximizing the sensitivity and specificity of CH calls through simulations
of leukocyte contamination in the tumor (see Bolton et al., Nature Genetics 2020
for more details). To further filter putative germline polymorphisms that passed the
blood/tumor solid tissue ratio due to allelic imbalance in the tumor specimen, we
removed any variant reported in any population in the gnomAD database at a
frequency >0.005.
KoCH cohort. Technically, the requirements to be called positive SNVs/insertions or
deletions all sequencing reads have a base-quality value of at least 20 and total read
numbers ≥10, Alt read numbers ≥10, positive Alt read numbers ≥5, negative Alt read
numbers ≥5, and VAF between 2% and 30%. We further filtered tri-allelic sites and
common germline variants with MAF ≥2% in gnomAD (genome aggregation data-
base v.2.1.1), the 1000 Genomes Project release 3, ESP6500 (Exome Sequencing Project
v. 6500), the ExAC (Exome Aggregation Consortium) data. At last, to remove technical
artifacts 1000 healthy individuals between age 40 and 49 year blood samples were
sequenced at depth of 1000×, and CH variant calls were made with the same CH calling
pipeline at VAF≥ 1%. Resulting variants with MAF ≥ 2% and not present in COSMIC
database were considered likely artifacts and were filtered.
Statistical analysis
CH and Covid-19 severity. We used multivariable logistic regression to evaluate for
an association between CH and Covid-19 severity adjusting for age (measured as a
continuous variable), gender, race, smoking history, and co-existing medical
comorbidities including diabetes, COPD/asthma, and cardiovascular disease all
classified as per Table 1. This was done separately for the MSK and KoCH cohorts.
For solid tumor patients at MSK we also adjusted for primary tumor site (thoracic
or non-thoracic cancer) and receipt of cytotoxic chemotherapy before and after
IMPACT blood draw. We also performed a sensitivity analysis adjusting for BMI
and the month of Covid-19 diagnosis. The OR estimates were largely unchanged;
in the model adjusted for BMI and month of Covid-19 diagnosis, this was 1.95
(95% CI 1.17–3.26, p= 0.01). A sensitivity analysis in the MSK-IMPACT cohort
limited to those who were not exposed to cytotoxic therapy prior to blood draw
yielded similar results (OR= 1.45; 95% CI 0.74–2.84) to those overall for the MSK-
IMPACT cohort. Graphical inspection of the frequency of CH by Covid-19 severity
stratified by age group and tumor type (for the MSK cohort) suggested that the
enrichment of CH among those with severe Covid-19 was not driven by a single
age group or tumor type (Supplementary Figs. 5–6).
Given the evidence of similarity in predictors of Covid-19 severity in cancer
and non-cancer populations13,19–21, we hypothesized that the effect of CH on
Covid-19 might be comparable between cancer and non-cancer populations. We
performed a fixed-effects meta-analysis (using the inverse-variance method in the
R package “Metafor”26) of the MSK and KoCH cohorts to jointly estimate the
odds ratio for severe Covid-19 among CH-positive compared with CH-negative
individuals.
CH and risk of infection in the MSK cohort. We analyzed billing codes from
14,211 solid tumor patients at MSKCC who had their blood sequenced using MSK-
IMPACT. We applied the phecode nomenclature developed at Vanderbilt6 to map
ICD-9 and ICD-10 billing codes to infectious disease subtypes. Subjects who were
billed using an ICD-9/10 code within the phecode for the first time following their
sequencing blood draw with evidence of CH were considered to have an incident
infection. Those who were billed for an ICD-9/10 code within the phecode prior to
the blood draw were removed from the analysis of that phecode. In order to
evaluate the accuracy of the billing code data, the presence of a documented C.
Difficile or Streptococcus infection in an EMR physician note was manually checked
for patients respectively identified by billing codes (N= 525 patients) by three
independent physicians using shared criteria for infection onset. Billing codes were
highly accurate in identifying the presence of the respective infectious disease
(concordance >95%).
We used Cox proportional hazards regression to estimate the HR for risk of
infection among those with CH compared with CH-negative individuals. The date
of blood draw (used for MSK-IMPACT sequencing) served as the onset date for
this time-to-event analysis; the end date was the date of billing code entry for the
infectious disease subtype phecode, death, or last follow-up, whichever came first.
All models were adjusted for age, gender, race, smoking, tumor type, and
cumulative exposure to cytotoxic chemotherapy prior to the blood draw and after
blood draw as previously described10. Following the 10:1 rule regarding the number
of covariates in a multivariable model in proportion to the number of events16, we
excluded infection subclasses populated with <80 individuals. The analysis utilized
multiplicity correction with the Benjamini–Hochberg method to establish adjusted
q values for HR with a prespecified FDR <0.10. Given the strong relationship
between prior antibiotic use and C. Difficile infection risk, we performed a
sensitivity analysis including the number of courses of antibiotics received after
MSK-IMPACT blood draw. There was no clear association between CH and
antibiotic use and no effect of inclusion of this as a covariate in the model
(Supplementary Fig. 5). Having a history of foley catheter (FC) and/or central
venous catheter (CVC) placement was common (37% and 20%, respectively) and
more frequent in those who also had a history of streptococcus/enterococcus
infection (48% and 34%, respectively). However, similar frequencies of FC and
CVC were observed among those with CH (36% and 19%) and without CH (38%
and 21%, respectively). Inclusion of a history of FC and CVC placement in the Cox
model for risk of streptococcus/enterococcus infection did not impact the HR for
CH (HR= 1.58, 95% CI 1.15–2.17, p= 0.004).
All the statistical analyses were performed with the use of the R statistical
package (www.r-project.org).
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All results derived from analysis of clinical sequencing data (CH mutations) for all
patients as well as the clinical data (for both the MSK-IMPACT and KoCH cohort)
necessary to replicate the findings in the article are available within the Article,
Supplementary Data, and on Github: https://github.com/kbolton-lab/papers/tree/main/
CH_COVID_NatureComm2021 and Zenodo (https://doi.org/10.5281/zenodo.5293522).
The raw sequencing data for the MSK-IMPACT and KoCH cohorts are protected and are
not broadly available due to privacy laws. Raw data elements may be requested from
zehira@mskcc.org (for MSK-IMPACT) and go01@snu.ac.kr (for KoCH) with
appropriate institutional approvals.
Received: 13 April 2021; Accepted: 10 September 2021;
References
1. Bick Alexander, G. et al. Genetic interleukin 6 signaling deficiency attenuates
cardiovascular risk in clonal hematopoiesis. Circulation 141, 124–131 (2020).
2. Bick, A. G. et al. Inherited causes of clonal haematopoiesis in 97,691 whole
genomes. Nature 1–7 https://doi.org/10.1038/s41586-020-2819-2 (2020).
3. Sano, S. et al. Tet2-mediated clonal hematopoiesis accelerates heart failure
through a mechanism involving the IL-1β/NLRP3 inflammasome. J. Am. Coll.
Cardiol. 71, 875–886 (2018).
4. Cai, Z. et al. Inhibition of inflammatory signaling in Tet2 mutant preleukemic
cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell
Stem Cell 23, 833–849.e5 (2018).
5. Zink, F. et al. Clonal hematopoiesis, with and without candidate driver
mutations, is common in the elderly. Blood 130, 742–752 (2017).
6. Poon, G., Watson, C. J., Fisher, D. S. & Blundell, J. R. Synonymous mutations
reveal genome-wide driver mutation rates in healthy tissues. bioRxiv https://
doi.org/10.1101/2020.10.08.331405 (2020).
7. Loh, P.-R. et al. Insights into clonal haematopoiesis from 8,342 mosaic
chromosomal alterations. Nature 559, 350–355 (2018).
8. Terao, C. et al. Chromosomal alterations among age-related haematopoietic
clones in Japan. Nature 584, 130–135 (2020).
9. Elizabeth, L. et al. Divergent Effects of Dnmt3a and Tet2 Mutations on
Hematopoietic Progenitor Cell Fitness. Stem Cell Reports 14, 551–560 https://
doi.org/10.1016/j.stemcr.2020.02.011 (2020).
10. Jaiswal, S. et al. Clonal hematopoiesis and risk for atherosclerotic
cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).
11. Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a
Tet2-deficient host. Nature 557, 580–584 (2018).
12. Zeng, H. et al. Antibiotic treatment ameliorates Ten-eleven translocation 2
(TET2) loss-of-function associated hematological malignancies. Cancer Lett.
467, 1–8 (2019).
13. Jee, J. et al. Chemotherapy and Covid-19 outcomes in patients with cancer. J.
Clin. Oncol. 38, 3538–3546 (2020).
14. Guan, W. et al. Clinical characteristics of coronavirus disease 2019 in China.
N. Engl. J. Med. 382, 1708–1720 (2020).
15. Livingston, E. & Bucher, K. Coronavirus disease 2019 (Covid-19) in Italy.
JAMA 323, 1335 (2020).
16. Petrilli, C. M. et al. Factors associated with hospital admission and critical
illness among 5279 people with coronavirus disease 2019 in New York City:
prospective cohort study. BMJ 369, m1966 (2020).
17. Sung, H. K. et al. Clinical course and outcomes of 3,060 patients with coronavirus
disease 2019 in Korea, January-May 2020. J. Korean Med. Sci. 35, e280 (2020).
18. Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal
hematopoiesis. Nat. Genet. 52, 1219–1226 (2020).
19. Kuderer, N. M. et al. Clinical impact of Covid-19 on patients with cancer
(CCC19): a cohort study. Lancet 395, 1907–1918 (2020).
20. Brar, G. et al. Covid-19 severity and outcomes in patients with cancer: a
matched cohort study. J. Clin. Oncol. 38, 3914–3924 (2020).
21. Yang, J. et al. Prevalence of comorbidities and its effects in patients infected
with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis.
94, 91–95 (2020).
22. Hameister, E. et al. Clonal hematopoiesis in hospitalized elderly patients with
Covid-19. HemaSphere 4, e453 (2020).
23. Wu, P. et al. Mapping ICD-10 and ICD-10-CM codes to phecodes: workflow
development and initial evaluation. JMIR Med. Inform. 7, e14325 (2019).
24. Zekavat, S. M. et al. Hematopoietic mosaic chromosomal alterations increase
the risk for diverse types of infection. Nat. Med. 27, 1012–1024 (2021).
25. Phi, J. H. et al. NPM1 as a potential therapeutic target for atypical teratoid/
rhabdoid tumors. BMC Cancer 19, 848 (2019).
26. Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J.
Stat. Softw. 36, 1–48 (2010).
Acknowledgements
This work was supported by the National Institute of Health (K08CA241318 to K.L.B,
P50 CA172012 to L.B., T32-CA009207 to J.J.), American Society of Hematology (K.L.B.),
EvansMDS Foundation (K.L.B.), European Hematology Association (E.P.), Gabrielle’s
Angels Foundation (E.P.), V Foundation (E.P.), Geoffrey Beene Foundation (E.P), Starr
Cancer Consortium (to R.L., A.Z., M.B, R.P.), and the Cancer Colorectal Cancer Dream
Team Translational Research Grant (SU2C-AACR-DT22-17 to L.D.). E.P. is a Josie
Robertson Investigator. M.M. is supported by funds from the Intramural Research
Program of the National Cancer Institute, National Institutes of Health. The KoCH
cohort was supported through a grant from the Korea Health Technology R&D Project
through the Korea Health Industry Development Institute (KHIDI), funded by the
Ministry of Health & Welfare, Republic of Korea (grant number: HI14C1277). We thank
the Global Science experimental Data hub Center (GSDC) and Korea Research Envir-
onment Open NETwork (KREONET) service for data computing and network provided
by the Korea Institute of Science and Technology Information (KISTI). Work performed
at Memorial Sloan Kettering Cancer Center was supported in part by the Cancer Center
Support Grant (grant no. P30 CA008748), the Marie Josee and Henry R Kravis Center
for Molecular Oncology, Cycle for Survival, and MSK Molecular Diagnostics Service.
Author contributions
K.L.B., M.B.F., J.Jee., A.S., Y.K., H.I., C.H.S., L.A.D., L.N., R.L.L., P.N., M.J.M., P.A., E.S.K.,
N.J.K., A.Z conceived and designed the study. K.L.B., M.B.F., J.Jee., K.A.T., C.H.S., A.S.,
J.H.M., J.Y.L., J.J., C.K.K., K.S., P.G.C., W.B.P., L.Z.B., H.B.K., M.O., H.S., S.K., M.P., E.S.K.,
N.J.K. performed collection of clinical data. K.L.B., H.I., R.P., E.G., A.S., T.G., E.P., M.L.,
M.F.B., C.H.S., A.Z led the generation and analysis of sequencing data. K.L.B., M.B.F., K.O.,
V.J., J.Jee., A.S., A.D., N.E.B., M.S.P., M.K., Y.K., H.I., B.J.W., I.C.C., M.J.R., C.H.S., S.K., H.S.,
A.Z., performed statistical analyses and/or participated in data interpretation. All authors
contributed to the writing of the manuscript and approved it for submission.
Competing interests
The authors declare the following competing interests: K.B. has received research funding
from GRAIL and Bristol Myers Squibb; Y.K. is a co-founder in Genome Opinion. M.F.B. is on
the advisory board for Roche and receives research support from Illumina. J.J. has a patent
licensed by the company MDSeq Inc. R.L.L. is on the supervisory board of Qiagen and is a
scientific advisor to Loxo, Imago, C4 Therapeutics, and Isoplexis, which include equity
interest. He receives research support from and consulted for Celgene and Roche and has
consulted for Lilly, Janssen, Astellas, Morphosys, and Novartis. He has received honoraria
from Roche, Lilly, and Amgen for invited lectures and from Gilead for grant reviews. A.Z.
received honoraria from Illumina. E.P. receives research funding from Celgene. D.G. and has
received honoraria for speaking and scientific advisory engagements with Celgene, Prime
Oncology, Novartis, Illumina, and Kyowa Hakko Kirin and is a co-founder in Isabl Tech-
nologies. M. Ladanyi has served on the advisory boards for AstraZeneca, Bristol Myers
Squibb, Takeda, Bayer, BluePrint, Pfizer, Janssen, and Merck, and has received research
support from Loxo Oncology and Helsinn Therapeutics, and Elevation Oncology. L.A.D. is a
member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce
Therapeutics; is a paid consultant to PGDx and Neophore; is an uncompensated consultant
for Merck (with the exception of travel and research support for clinical trials); is an inventor
of multiple licensed patents related to technology for circulating tumor DNA analyses and
mismatch repair deficiency for diagnosis and therapy from Johns Hopkins University, some of
which are associated with equity or royalty payments directly to Johns Hopkins and L.A.D.;
and holds equity in PGDx, Jounce Therapeutics, Thrive Earlier Detection and Neophore; his
wife holds equity in Amgen. The terms of all of these arrangements are being managed by
Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest
policies. H.I., C.H.S., H.S., S.K. are current employees of Genome Opinion and holds stock in
the company. All other authors declare no competing interests.
Additional information
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41467-021-26138-6.
Correspondence and requests for materials should be addressed to Kelly L. Bolton,
Eu Suk Kim, Nam Joong Kim or Ahmet Zehir.
Peer review information Nature Communications thanks the anonymous reviewer(s) for
their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26138-6 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:5975 | https://doi.org/10.1038/s41467-021-26138-6 | www.nature.com/naturecommunications 7
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021
1Department of Medicine, Washington University, St Louis, MO, USA. 2Department of Internal Medicine, Seoul National University Hospital,
Seoul, Korea. 3Genome Opinion Inc., Seoul, Korea. 4Center for Precision Medicine, Seoul National University Hospital, Seoul, Korea. 5Department
of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6Department of Pathology, Memorial Sloan Kettering Cancer Center,
New York, NY, USA. 7Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National
University, Daegu, Korea. 8Department of Internal Medicine, National Medical Center, Seoul, Korea. 9Department of Internal Medicine, Seoul
National University Bundang Hospital, Seongnam, Korea. 10Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New
York, NY, USA. 11Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12Department of
Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 13Computational Oncology Service, Department of
Epidemiology & Biostatistics, Center for Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 14Department
of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 15Department of Pathology and Molecular Medicine,
Queen’s University, Kingston, ON, Canada. 16Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA. 17Department
of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. 18Division of Cancer Epidemiology and Genetics,
National Cancer Institute, Bethesda, MD, USA. 19Ontario Institute for Cancer Research, Toronto, ON, Canada. 20Clinical Genetics Research Lab,
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 21These authors contributed equally: Kelly L. Bolton,
Youngil Koh, Michael B. Foote, Hogune Im, Justin Jee, Choong Hyun Sun, Anton Safonov, Eu Suk Kim, Nam Joong Kim, Ahmet Zehir.
✉email: bolton@wustl.edu; eskim@snubh.org; molder@unitel.co.kr; zehira@mskcc.org
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26138-6
8 NATURE COMMUNICATIONS |         (2021) 12:5975 | https://doi.org/10.1038/s41467-021-26138-6 | www.nature.com/naturecommunications
